{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-284633","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.938084+00:00","generated_at":"2026-05-16T19:07:44.437207+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enanta Q4 net loss $0.87/sh, revenue $15.1M; cash $188.9M; RSV data positive, STAT6 candidate selected","bullets":["Net loss $18.7M ($0.87 loss per share) vs $28.8M loss ($1.36/sh) in Q4 2024.","Total revenue $15.1M from MAVYRET royalties; FY 2025 revenue $65.3M vs $67.6M prior year.","Ending cash $188.9M; plus $74.8M gross from Oct 2025 offering; runway into FY2029.","Zelicapavir Phase 2b in high-risk RSV adults met secondary endpoints; 2.2-day symptom resolution improvement.","Nominated EPS-3903 (STAT6 inhibitor) with >90% pSTAT6 suppression; IND target H2 2026; EDP-978 IND Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-284633","json":"https://secwatch.observer/filing/0001193125-25-284633.json","markdown":"https://secwatch.observer/filing/0001193125-25-284633.md","text":"https://secwatch.observer/filing/0001193125-25-284633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312525284633/0001193125-25-284633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312525284633/enta-20251117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:07:44.437207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}